Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy

Open access
Iorga, Andrea, Cunningham, Christine M., Moazeni, Shayan, Ruffenach, Gregoire, Umar, Soban, Eghbali, Mansoureh · 2017 · Biology of Sex Differences

Abstract

Epidemiologic studies have previously suggested that premenopausal females have reduced incidence of cardiovascular disease (CVD) when compared to age-matched males, and the incidence and severity of CVD increases postmenopause. The lower incidence of cardiovascular disease in women during reproductive age is attributed at least in part to estrogen (E2). E2 binds to the traditional E2 receptors (ERs), estrogen receptor alpha (ERα), and estrogen receptor beta (ERβ), as well as the more recently identified G-protein-coupled ER (GPR30), and can exert both genomic and non-genomic actions. This review summarizes the protective role of E2 and its receptors in the cardiovascular system and discusses its underlying mechanisms with an emphasis on oxidative stress, fibrosis, angiogenesis, and vascular function. This review also presents the sexual dimorphic role of ERs in modulating E2 action in cardiovascular disease. The controversies surrounding the clinical use of exogenous E2 as a therapeutic agent for cardiovascular disease in women due to the possible risks of thrombotic events, cancers, and arrhythmia are also discussed. Endogenous local E2 biosynthesis from the conversion of testosterone to E2 via aromatase enzyme offers a novel therapeutic paradigm. Targeting specific ERs in the cardiovascular system may result in novel and possibly safer therapeutic options for cardiovascular protection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13293-017-0152-8

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Genomic and non-genomic actions of E2. E2 can regulate gene expression and activity of signaling molecules by binding to ERs via genomic and/or non-genomic pathways. In genomic regulation, binding of E2 to the ER promotes the formation of homo/hetero dimers, translocation to the nucleus and direct binding to estrogen response elements (ERE), or to transcription factors which regulate transcription of its target genes including VEGF, a pro-angiogenic factor. In non-genomic regulation, binding of E2 to ERs and GPR30 at the plasma membrane leads to activation of MAPK/ERK/PI3K/cAMP, which induce gene expression including eNOS, a potent vasodilator. E2 also binds to ERs localized on the mitochondrial membrane improving mitochondrial function by decreasing ROS production and increasing cell survival. Local E2 biosynthesis from the conversion of T to E2 via aromatase (CYP450) is also shown. Genomic pathways are shown in red arrows, whereas non-genomic pathways are shown in blue arrows. Abbreviations: E2 estrogen, ER estrogen receptor, ERE estrogen response element, T testosterone, GPCR G-protein-coupled receptor, PI3K phosphoinositide 3-kinase, MAPK mitogen activated protein kinase, AKT protein kinase B, VEGF vascular endothelial growth factor
Fig. 1 Genomic and non-genomic actions of E2. E2 can regulate gene expression and activity of signaling molecules by binding to ERs via genomic and/or non-genomic pathways. In genomic regulation, binding of E2 to the ER promotes the formation of homo/hetero dimers, translocation to the nucleus and direct binding to estrogen response elements (ERE), or to transcription factors which regulate transcription of its target genes including VEGF, a pro-angiogenic factor. In non-genomic regulation, binding of E2 to ERs and GPR30 at the plasma membrane leads to activation of MAPK/ERK/PI3K/cAMP, which induce gene expression including eNOS, a potent vasodilator. E2 also binds to ERs localized on the mitochondrial membrane improving mitochondrial function by decreasing ROS production and increasing cell survival. Local E2 biosynthesis from the conversion of T to E2 via aromatase (CYP450) is also shown. Genomic pathways are shown in red arrows, whereas non-genomic pathways are shown in blue arrows. Abbreviations: E2 estrogen, ER estrogen receptor, ERE estrogen response element, T testosterone, GPCR G-protein-coupled receptor, PI3K phosphoinositide 3-kinase, MAPK mitogen activated protein kinase, AKT protein kinase B, VEGF vascular endothelial growth factorCC BY · PubMed Central
Fig. 2 Summary of the likely protective mechanisms of estrogen against cardiovascular disease. Illustration of the possible beneficial effects of estrogen for the treatment of cardiovascular diseases such as ischemic heart disease and heart failure. The protective effect of estrogen in cardiovascular disease is associated with reduced fibrosis, stimulation of angiogenesis, and vasodilation, improved mitochondrial function, and reduced oxidative stress. Abbreviations: VEGF vascular endothelial growth factor, eNOS endothelial nitric oxide synthase, AngII angiotensin II, MMP2 matrix metalloproteinase 2, ROS reactive oxygen species, FAO fatty acid oxidation
Fig. 2 Summary of the likely protective mechanisms of estrogen against cardiovascular disease. Illustration of the possible beneficial effects of estrogen for the treatment of cardiovascular diseases such as ischemic heart disease and heart failure. The protective effect of estrogen in cardiovascular disease is associated with reduced fibrosis, stimulation of angiogenesis, and vasodilation, improved mitochondrial function, and reduced oxidative stress. Abbreviations: VEGF vascular endothelial growth factor, eNOS endothelial nitric oxide synthase, AngII angiotensin II, MMP2 matrix metalloproteinase 2, ROS reactive oxygen species, FAO fatty acid oxidationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 140 references

Research works printed but not linked: 1

  1. Pharmacodynamic effects of the fetal estrogen estetrol in... : menopause [Internet]. LWW. [cited 2017 Aug 24]. Available from: http://journals.lww.com/menopausejournal/Fulltext/2017/06000/Pharmacodynamic_effects_of_the_fetal_estrogen.13.aspx

Cited by

See all 1,000

Metadata

Authors
Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M.
Affiliations
  • University of Southern California (US)
  • University of California, Los Angeles (US)
Corresponding author
Eghbali, Mansoureh
Venue
Biology of Sex Differences
Published
2017-10-24
Volume
8
Issue
1
Pages
33-33
ISSN
2042-6410 (ISSN-L)
OpenAlex
W2766043255
Cited by
914
References
140
Citations by year
2026: 91 · 2025: 157 · 2024: 156 · 2023: 143 · 2022: 114 · 2021: 113 · 2020: 88 · 2019: 38 · 2018: 12 · 2017: 2
FWCI
4.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Biology of Sex Differences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • American Heart Association (AHA-17PRE33420159, AHA16GRANT27760058)
  • National Institutes of Health (R01HL131182-01A1, T32-GM065823, HD00722)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
Keywords
estrogen, estrogen receptor, estrogen receptor alpha, estrogen receptor beta, GPR30, cardiovascular disease, postmenopause, sex differences, oxidative stress, fibrosis, angiogenesis, vascular function, aromatase, thrombosis risk, cardioprotection
MeSH terms
Animals, Cardiovascular Agents, Cardiovascular Diseases, Estrogens, Humans, Receptors, Estrogen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. https://app.cochat.ai/papers/10.1186/s13293-017-0152-8
The paper
Iorga, A., Cunningham, C. M., Moazeni, S., Ruffenach, G., Umar, S., & Eghbali, M. (2017). The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biology of Sex Differences. https://doi.org/10.1186/s13293-017-0152-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.